Indonesia DIA-RAMADAN Study: A Real-life, Prospective and Observational of Gliclazide MR in Type-2 Diabetes Patients During Ramadan Fasting
Background: Sulfonylureas (SUs) have been widely used in many countries for T2DM treatment. Gliclazide is one of the SUs with the lowest risk of hypoglycemia; however, the safety and effectiveness of gliclazide MR during Ramadan has not yet been reported in Indonesia. This study aimed to assess safe...
Saved in:
| Main Authors: | Soebagijo Adi Soelistijo, Andi Makbul Aman, Hendra Zufry, Agung Pranoto, Achmad Rudijanto, Mohamed Hassanien |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Interna Publishing
2022-04-01
|
| Series: | Acta Medica Indonesiana |
| Subjects: | |
| Online Access: | http://www.actamedindones.org/index.php/ijim/article/view/1758 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Results of a 12-month follow-up of patients with type 2 diabetes mellitus after hospitalization with COVID-19: gliclazide MR use in the hospital and metabolic status at the posthospital stage
by: T. A. Nekrasova, et al.
Published: (2023-07-01) -
Low risk of hypoglycemia and high efficacy of gliclazide MB: results of recent studies
by: I. V. Kononenko, et al.
Published: (2021-11-01) -
Gliclazide MR in the structure of antihyperglycemic therapy according to the data of Moscow region diabetes register
by: I. V. Misnikova, et al.
Published: (2022-05-01) -
The place of gliclazide MB in modern treatment strategies for patients with type 2 diabetes mellitus
by: N. A. Petunina, et al.
Published: (2024-09-01) -
Effectiveness of ertugliflozin during Ramadan fasting in patients with type 2 diabetes mellitus: a real-world study (ErtuRamadan study)
by: Md Faruque Pathan, et al.
Published: (2025-02-01)